HTDS releases news - not much change in pps. I have 100K shares and I'm down 80%. I hope it gets bought out.
Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals
Last update: 2/5/2010 12:04:00 PM
BEIJING, CHINA, Feb 05, 2010 /PRNewswire via COMTEX/ -- Hard to Treat Diseases (HTDS; ) brings attention to a certain previously released news announcements namely January 7 2009, November 19, 2009, Dec 15, 2009 January 12,2010, and January 22, 2010.
These are significant dates and important events for the company as all of these events are now starting to crystallize and are beginning to transform HTDS from a Vaccine and a RD company to a much more diversified company encompassing several health care and cosmetics sectors. Firstly, In a certain news release dated Jan 7, 2009 - HTDS announced its desire to expand into the cosmetics field. Shortly thereafter HTDS acquired interest in a micro cosmetics company in East Europe. The cosmetics company Melem Secrets is engaged in online sales of the "Melem" product. Over the past 12 months, this division of HTDS slowly and while under the radar, continued developing contacts, networking, and doing business; while adding various new products and services. Shortly the company intends to unveil its new web site together with a launch of its cosmetic services. A new CEO of the cosmetics division only is planned including additional sales, and administrative staff. Shortly thereafter this division will start releasing its progresses made, contracts, and revenues. HTDS shareholders and followers by all accounts should pleasantly be surprised.
With the January 22, 2010 news release, the company entertained an unsolicited business proposal from an obstetrician type medical company. This Middle East Company is engaged in a treatment of pre-term labor and induction of labor. These symptoms affect millions of people worldwide. The company is pleased to report that it is in final short strokes of its negotiations with this targeted company. Details will be released shortly.
The company's Slavica Bio Chem division remains undisturbed. Slavica medical research activities include neurophysiologists, and molecular biologists working on neurological impairments in Multiple Sclerosis (MS) and Traumatic Brain Injury (TBI).
At the core of HTDS business is the China based Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Mellow Hope is the biggest exporter of Biological Vaccines in China. Based on the cooperation with Institutes of Medical Biology and Pharmaceutical manufacturers, Mellow Hope provides a wide range of vaccines with high quality, safety and efficacy. The company brings attention to a certain news release of Dec 15, 2009 and November 19, 2009 titled - "Hard To Treat Diseases (HTDS) Chilean first order of 200,000 doses". Significant progress on the aforementioned Chilean order has been achieved by HTDS. The company is hopeful that the details could be made available within the 1st Quarter of 2010.
In other news and events the company is in receipt of the 40 million shares from HIRU representing the sale of HTDS MindUp division. See link or see filing filling by HIRU with Pink Sheets dated January 29, 2010 Labeled Hiru Acquires Mind Up from Hard to Treat Diseases.
The Jan. 12 2010 news release is self explanatory. - Hard to Treat Diseases, Inc. (HTDS; announced that its directors have resolved that up to 40,000,000 shares of Hiru Corporation (HIRU.PK) HTDS received for the sale of its MindUp division to Hiru will be distributed to HTDS shareholder as a special onetime payment of kind.
Subsequently a 5-1 forward split was announced by HIRU which will affect HTDS for a distribution of about 200 million shares versus the original 40 million to our shareholders.
Moving forward assuming all of the above comes to fruition HTDS will have 4 unique and distinct operating subsidiaries in the health care and cosmetics - beauty aid sector. A source close to the company was asked if this configuration will remain permanent in HTDS? "The company will do whatever is in the best interest of the company and its shareholders. Nothing is written in stone. Should a suitable buyer come along at the right price and terms, everything is open for discussion. Right now there is no buyer in the wings or nothing in the works or on the horizon having just completed the sale of the MindUp project. We are disheartened that the governing or self regulatory bodies simply choose to do nothing and what appears to us chose to side with short sellers and "over sellers" instead of at least remaining neutral. We are pleased to see some of the stock bashers rained in with the recent court ruling which in its sense gave us our second wind, and the will to come back with a vengeance. The company remains committed to restore values as evidenced by the strides it made so far. The slow stream of news announcements in January and February 2010 (compared to the recent past) can best be defined as "the HTDS calm before the storm". I know that HTDS management continues to have aspirations of completing its audit and delivering on all promises made to its long term shareholders and followers. The best of HTDS is yet to come."
To be included in HTDS' email database for press releases and industry updates, please subscribe at or opt in with your email address at this link: .
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiries only, please contact medicalinfo@htdsmedical.com; for any corporate matters, please contact
SOURCE Hard to Treat Diseases
Copyright (C) 2010 PR Newswire. All rights reserved
Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.
News provided by Dow Jones NewswiresSM, PR News Wire™ and Business Wire™. Dow Jones Newswires is a service mark of Dow Jones & Company. PR News Wire is a Trademark of PR Newswire Association, Inc. Business Wire is a registered trademark and service mark of Business Wire.
Ameritrade is not responsible for the quality and suitability of third party financial or investment information or services. Please consult other sources of information and consider your individual financial position and goals before making an investment decision. Ameritrade, Division of Ameritrade, Inc., member NASD/SIPC. Ameritrade and Ameritrade logos are trademarks or registered trademarks of Ameritrade IP Company, Inc. 2002 Ameritrade IP Company, Inc. All rights reserved. Used with permission.
